Home >Research Technology Management>Technology for Licensing
Compounds for treating viral infections (Hepatitis C Virus)
US Provisional application 61/980,940.
Marc P. Windisch, Jonathan Cechetto
Stage of Development
Summary of Invention
The invention relates to a novel hepatitis C virus (HCV) inhibitor by phenotypically screening of small molecule libraries using infectious virions.
Approximately 3 percent of the world population is estimated to be infected with the hepatitis C virus. The demand market for HCV treatment is forecasted to reach 15 trillion won (USD $ 15 billions) by 2022. Development of a successful drug for HCV has a high potential of advancing into the global market with an annual revenue of 4 trillion won. These compounds are the novel drug candidates to treat HCV.